Emergent BioSolutions Inc. (EBS)
Largest Insider Buys in Sector
EBS Stock Price History Chart
EBS Stock Performance
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat …
Insider Activity of Emergent BioSolutions Inc.
Over the last 12 months, insiders at Emergent BioSolutions Inc. have bought $0 and sold $519,596 worth of Emergent BioSolutions Inc. stock.
On average, over the past 5 years, insiders at Emergent BioSolutions Inc. have bought $112,380 and sold $13.87M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,000 shares for transaction amount of $112,380 was made by LINDAHL RICHARD S (EVP, Chief Financial Officer) on 2021‑11‑15.
List of Insider Buy and Sell Transactions, Emergent BioSolutions Inc.
| 2024-11-12 | Sale | director | 25,000 0.0461% | $10.91 | $272,750 | -18.46% | ||
| 2024-11-11 | Sale | director | 14,287 0.0264% | $11.97 | $171,015 | -21.26% | ||
| 2024-06-04 | Sale | director | 10,000 0.021% | $6.11 | $61,100 | +60.25% | ||
| 2024-05-29 | Sale | director | 1,830 0.0035% | $4.61 | $8,436 | +89.01% | ||
| 2024-05-21 | Sale | director | 1,089 0.0023% | $5.78 | $6,294 | +63.32% | ||
| 2023-06-02 | Sale | director | 1,830 0.0037% | $8.35 | $15,281 | -68.08% | ||
| 2023-05-25 | Sale | director | 1,700 0.0035% | $8.38 | $14,246 | -67.30% | ||
| 2022-11-25 | Sale | director | 1,912 0.0038% | $11.94 | $22,829 | -29.50% | ||
| 2022-06-09 | Sale | 1,173 0.0023% | $31.52 | $36,973 | -57.24% | |||
| 2022-05-24 | Sale | 1,996 0.0043% | $35.53 | $70,918 | -58.06% | |||
| 2021-11-15 | EVP, Chief Financial Officer | 3,000 0.0055% | $37.46 | $112,380 | -11.87% | |||
| 2021-05-25 | Sale | director | 3,139 0.0058% | $56.48 | $177,291 | -17.33% | ||
| 2021-03-04 | Sale | director | 8,168 0.0156% | $92.37 | $754,478 | -36.39% | ||
| 2021-03-01 | Sale | EVP, Business Operations | 37,279 0.068% | $99.30 | $3.7M | -42.76% | ||
| 2021-02-08 | Sale | President and CEO | 13,000 0.0237% | $120.03 | $1.56M | -51.36% | ||
| 2021-01-21 | Sale | President and CEO | 21,900 0.0411% | $110.03 | $2.41M | -44.59% | ||
| 2021-01-20 | Sale | President and CEO | 2,232 0.0043% | $110.00 | $245,520 | -43.44% | ||
| 2021-01-15 | Sale | President and CEO | 19,026 0.0356% | $106.01 | $2.02M | -42.45% | ||
| 2020-11-10 | Sale | Chairman | 19,391 0.0371% | $88.21 | $1.71M | -27.09% | ||
| 2020-11-09 | Sale | Chairman | 20,000 0.0403% | $95.26 | $1.91M | -28.70% |
Insider Historical Profitability
| Abdun-Nabi Daniel | CEO | 142617 0.2632% | $9.39 | 2 | 48 | +48.31% |
| LINDAHL RICHARD S | EVP, Chief Financial Officer | 39919 0.0737% | $9.39 | 1 | 0 | <0.0001% |
| Havey Adam | EVP, Business Operations | 38190 0.0705% | $9.39 | 1 | 24 | +10.39% |
| Elsey R Don | Chief Financial Officer | 22199 0.041% | $9.39 | 1 | 9 | <0.0001% |
| Zink Thomas | SVP & CMO | 990 0.0018% | $9.39 | 2 | 0 | <0.0001% |
Institutional Investor Ownership
| BlackRock | $17.86M | 13.47 | 7.06M | -24.89% | -$5.92M | <0.0001 | |
| Charles Schwab | $10.5M | 7.92 | 4.15M | +44.45% | +$3.23M | <0.01 | |
| The Vanguard Group | $8.63M | 6.51 | 3.41M | +14.69% | +$1.11M | <0.0001 | |
| Avidity Partners Management Lp | $4.83M | 3.64 | 1.91M | New | +$4.83M | 0.18 | |
| Morgan Stanley | $3.27M | 2.47 | 1.29M | +4.72% | +$147,615.42 | <0.0001 |